anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: The purpose of this study was to evaluate the efficacy of recombinant human superoxide dismutase (rhSOD) enemas in radiation-induced acute rectal injury (RARI) in patients with locally advanced cervical cancer.
METHODS AND MATERIALS: In this phase 3, randomized, open-label trial (NCT04819685) conducted across 14 medical centers in China from June 2021 to August 2023, all patients received concurrent chemoradiation therapy (CCRT). The experimental group was treated with a rhSOD enema during chemoradiation therapy, and the control group had no enema. The Common Terminology Criteria for Adverse Events (version 5.0) was used to evaluate radiation therapy-induced side effects. Endoscopic appearance was assessed using the Vienna Rectoscopy Score. The primary endpoint in the acute phase was the occurrence rate and duration of grade ≥1 (≥G1) diarrhea during CCRT. Secondary endpoints included the occurrence rate and duration of ≥G2 and ≥G3 diarrhea, ≥G1 and ≥G2 diarrhea lasting at least 3 days, and damage to the rectal mucosa due to radiation therapy measured by endoscopy.
RESULTS: Two hundred and eighty-three patients were randomly divided into the experimental (n = 141) or control group (n = 142). The mean number of ≥G1 and ≥G2 diarrhea days were significantly lower in the experimental group than in the control group (3.5 and 0.8 days vs 14.8 and 4.5 days, respectively; P < .001). The incidence of ≥G2 diarrhea decreased from 53.6% to 24.1% when rhSOD enemas were used. Use of antidiarrheals was lower in the experimental group (36.2% vs 55.7%, P < .001). Three patients felt intolerable or abdominal pain after rhSOD enema. RARI grades in the experimental group tended to be lower than those in the control group (P = .061). Logistic regression analysis revealed that rhSOD enema was associated with a lower occurrence rate of ≥G1/2 diarrhea for at least 3 days (P < .001).
CONCLUSIONS: The results of this study suggest that rhSOD enema is safe and significantly reduces the incidence, severity, and duration of RARI, protecting the rectal mucosa.
A pump unit ( 10 ) includes a number of pumps ( 14 ) each having a port in fluid connection to a combined port ( 12 ) of the pump unit. A processing system ( 16 ) is connected to each of the pumps ( 14 ) for independent actuation of each pump. A user interface ( 22 ) allows user actuation of the pump unit according to one or more mode of operation, requiring various different levels of suction or pressure. The processing system ( 16 ) determines what number of pumps ( 14 ) is required, and selectively actuates pumps in order to generate the required suction or pressure. Particularly preferred applications include breast pumps. Additional aspects of the invention relate to a cyclic pulsed suction profile generated by the device, implementations that detect when a milk extraction set is not properly deployed, and configurations which allow a touch screen to be used as a power-on switch for the device.
This is a controled, randomized, double blind, two arms clinical trial. The main objective of this study is to evaluate the effect of photobiomodulation with amber light in the treatment of Melasma compared to the effect of tranexamic acid. The sample will be divided into 2 groups: Group 1 will receive PBM with amber Light Emitting Diode (LED) (DMC E-Light ABR), 20 J/cm² and placebo topical cosmetic for use in home care; Group 2 will receive PBM sham and topical cosmetic containing 5% liposomal tranexamic acid for use in home care. A total of 54 women with facial Melasma, aged 35 to 50 will be included. The treatments will consist of 12 sessions, once a week for 3 months. The severity of Melasma will be evaluated through the Melasma Area and Severity Index (MASI index), the pigmentation of the epidermis will be evaluated by corneomelametry, photographic records and the quality of life questionnaire (MELASQoL-PB) will also be made.
Methods of treating a nerve injury are disclosed. The methods include administering to a target site of the nerve injury a thermally stable preparation having a purified amphiphilic peptide in an aqueous biocompatible solution, being configured to self-assemble into a hydrogel, and administering to the target site a buffer having an effective amount of an ionic salt and a biological buffering agent to form the hydrogel. The methods include administering to the target site a biological material suspension in an amount effective to treat the nerve injury. The methods include administering to the target site an anti-scarring agent in an amount effective to treat the nerve injury. The target site is associated with central nervous system tissue or peripheral nervous system tissue. The nerve injury includes spinal cord injury and peripheral nerve injury.
The protocol is same as the previous study: pcTBS was administered to the left M1 at 80% resting motor threshold (RMT), consisting of a burst of 3 pulses given at 50 Hz repeated every 5 Hz using repetitive transcranial magnetic stimulation device . A total of 1,200 pulses were delivered with the TMS coil positioned in a posterior-anterior (PA) direction parallel to the midline.
Participants will be randomized to either start to receive high-oleic sunflower oil (HOSO) for 6 weeks. Followed by a wash-out period of minimum 12 weeks, before the treatment is changed.
The present invention provides an isolated nucleic acid sequence encoding murine IL-2Rγ. The present invention also provides a vector comprising a mutated IL-2Rγ nucleic acid which is capable of homologous recombination in at least some cells to which the vector is introduced. The present invention also provides an embryonic stem cell comprising a mutated IL-2Rγ nucleic acid integrated into the cell by homologous recombination following transfection with the vector above. The present invention further provides a blastocyst cell comprising the embryonic stem cell above. In addition, the present invention provides a transgenic animal comprising a mutated IL-2Rγ gene. In particular, the animal is a non-human mammal whose germ and somatic cells contain a mutated IL-2Rγ gene sequence introduced into said mammal, or an ancestor thereof, at an embryonic stage. The present invention also provides a method of producing a non-human mammal with XSCID which comprises introducing into at least some cells of the recipient animal a mutated IL-2Rγ gene. Lastly, the present invention provides a non-human animal produced by the method above, and progeny thereof, wherein at least some cells retain a mutated IL-2Rγ gene.
Participants enrolled in this study protocol will receive daily intravenous (IV) infusions of carfilzomib for a total of 4 days (Day-9, -8 and Days -2, -1). The first two daily infusions will be given at a fixed dose of 20 mg/m2 and the final two doses will be escalated from the standard dose of 27 mg/m2 to 56 mg/m2 in a Phase I design, based on toxicity. The busulfan will be administered for 2 days over 3 hours from D-7, -6, at 130 mg/m2 . This dose was found to be safe and equivalent to the standard daily dose of 3.2 mg/kg. The 3rd and 4th daily doses of IV Busulfan will be adjusted in order to yield a systemic plasma drug exposure represented by a daily area under the plasma concentration versus time curve (AUC) of approximately 5,000 millimoles-minute per dose (mM-min). These targeted plasma concentration of IV busulfan will be based on pharmacokinetics studies performed during the first day of IV busulfan. Melphalan will be given at a dose of 140 mg/m2 on Day -3. Each cohort will start with a goal of accruing three patients to determine the dose limiting toxicity.
BACKGROUND: Psychoneuroimmunological mechanisms and the gut-brain axis appear relevant to disease activity and progression in Inflammatory Bowel Disease (IBD). A recent review showed no effect of psychological therapies on self-reported disease activity in IBD. This meta-analysis aims to establish whether interventions targeting mood outcomes (e.g., depression, anxiety and stress) impact inflammation levels in IBD and possible moderators of these effects.
METHODS: The Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines were followed. We searched five electronic databases and included randomised controlled trials where interventions targeted mood and assessed inflammatory outcomes pre- and post-intervention in adults with IBD. Independent reviewers screened studies, extracted data, and assessed methodological quality. Data were pooled to estimate standardised mean differences (SMDs) with 95% Confidence Intervals (CIs). A random-effects robust variance estimation accounted for studies measuring multiple biomarkers. Intervention type, mood as a primary or secondary outcome, effect on mood outcomes and IBD subtype were investigated as treatment effect moderators. Where there were sufficient biomarkers, individual meta-analyses were run (Pre-registration PROSPERO: CRD42023389401).
FINDINGS: 28 RCTs involving 1789 participants met inclusion criteria. Interventions demonstrated small, statistically significant effects on biomarkers (-0.35, 95% CI: -0.48, -0.22, p < 0.001) and medium effects on mood outcomes (-0.50, 95% CI: -0.73, -0.27, p < 0.001), without evidence of substantive heterogeneity or publication bias. Individual analyses showed small effects for improved faecal calprotectin (-0.19, 95% CI: -0.34, -0.03, p = 0.018) and C-Reactive Protein (-0.29, 95% CI: -0.47, -0.10, p = 0.002). Effect sizes were larger for psychological therapy interventions (compared with exercise or antidepressants) and when there was an effect (SMD ≥0.2) on mood.
INTERPRETATION: Treatments which address mood outcomes have beneficial effects on generic inflammation as well as disease-specific biomarkers (faecal calprotectin and C-Reactive Protein). Psychological interventions and interventions with larger treatment effects on mood accentuated the effect on biomarkers. More research is required to understand the biological or behavioural mechanisms underlying this effect.
FUNDING: The Medical Research Council and the National Institute for Health and Care Research (NIHR) Maudsley Biomedical Research Centre.
Due to its benzyl alcohol content, Glycopyrrolate Injection should not be used in neonates, i.e., patients less than 1 month of age. 

Safety and effectiveness in pediatric patients have not been established for the management of peptic ulcer.

Dysrhythmias associated with the use of glycopyrrolate intravenously as a premedicant or during anesthesia have been observed in pediatric patients.

Infants, patients with Down's syndrome, and pediatric patients with spastic paralysis or brain damage may experience an increased response to anticholinergics, thus increasing the potential for side effects.

A paradoxical reaction characterized by hyperexcitability may occur in pediatric patients taking large doses of anticholinergics including Glycopyrrolate Injection. Infants and young children are especially susceptible to the toxic effects of anticholinergics. 

Benzyl alcohol, a component of this drug product, has been associated with serious adverse events and death, particularly in pediatric patients. The "gasping syndrome," (characterized by central nervous system depression, metabolic acidosis, gasping respirations, and high levels of benzyl alcohol and its metabolites found in the blood and urine) has been associated with benzyl alcohol dosages >99 mg/kg/day in neonates and low-birth-weight neonates. Additional symptoms may include gradual neurological deterioration, seizures, intracranial hemorrhage, hemotologic abnormalities, skin breakdown, hepatic and renal failure, hypotension, bradycardia, and cardiovascular collapse. Although normal therapeutic doses of this product deliver amounts of benzyl alcohol that are substantially lower than those reported in association with the "gasping syndrome," the minimum amount of benzyl alcohol at which toxicity may occur is not known. Premature and low-birthweight infants, as well as patients receiving high dosages, may be more likely to develop toxicity. Practitioners administering this and other medications containing benzyl alcohol should consider the combined daily metabolic load of benzyl alcohol from all sources.
During aging, general cellular processes, including autophagic clearance and immunological responses become compromised; therefore, identifying compounds that target these cellular processes is an important approach to improve our health span. The innate immune cGAS-STING pathway has emerged as an important signaling system in the organismal defense against viral and bacterial infections, inflammatory responses to cellular damage, regulation of autophagy, and tumor immunosurveillance. These key functions of the cGAS-STING pathway make it an attractive target for pharmacological intervention in disease treatments and in controlling inflammation and immunity. Here, we show that urolithin A (UA), an ellagic acid metabolite, exerts a profound effect on the expression of STING and enhances cGAS-STING activation and cytosolic DNA clearance in human cell lines. Animal laboratory models and limited human trials have reported no obvious adverse effects of UA administration. Thus, the use of UA alone or in combination with other pharmacological compounds may present a potential therapeutic approach in the treatment of human diseases that involves aberrant activation of the cGAS-STING pathway or accumulation of cytosolic DNA and this warrants further investigation in relevant transgenic animal models.
AIMS: Reverse shoulder arthroplasty (RSA) has become the most common type of shoulder arthroplasty used in the UK, and a better understanding of the outcomes after revision of a failed RSA is needed. The aim of this study was to review the current evidence systematically to determine patient-reported outcome measures and the rates of re-revision and complications for patients undergoing revision of a RSA.
METHODS: MEDLINE, Embase, CENTRAL, and the Cochrane Database of Systematic Reviews were searched. Studies involving adult patients who underwent revision of a primary RSA for any indication were included. Those who underwent a RSA for failure of a total shoulder arthroplasty or hemiarthroplasty were excluded. Pre- and postoperative shoulder scores were evaluated in a random effects meta-analysis to determine the mean difference. The rates of re-revision and complications were also calculated.
RESULTS: The initial search elicited 3,166 results and, following removal of duplicates and screening, 13 studies with a total of 1,042 RSAs were identified. An increase in shoulder scores pre- to postoperatively was reported in all the studies. Following revision of a RSA to a further RSA, there was a significant increase in the American Shoulder and Elbow Surgeons Score (mean difference 20.78 (95% CI 8.16 to 33.40); p = 0.001). A re-revision rate at final follow-up ranging from 9% to 32%, a one-year re-revision rate of 14%, and a five-year re-revision rate of 23% were reported. The complication rate in all the studies was between 18.5% and 36%, with a total incidence of 29%.
CONCLUSION: This is the largest systematic review of the outcomes following revision of a RSA. We found an improvement in functional outcomes after revision surgery, but the rates of re-revision and complications are high and warrant consideration when planning a revision procedure.
Participants will receive roxadustat, administered orally 3 times per week (TIW) for 12 weeks to achieve Hb levels of 100-120 g/L. The starting dose will be based on the participant's weight group. The maximum dose for individual participants may not exceed 3.5 milligrams (mg)/kilogram (kg) or 400 mg TIW whichever is lower.
Participants will first have a procedure to collect your white blood cells that will be used to make axicabtagene ciloleucel. Then participatns will receive radiation therapy, followed by conditioning chemotherapy and 1 infusion of axicabtagene ciloleucel.
There have been postmarketing reports of fatal and non-fatal hepatic failure in patients taking pioglitazone, although the reports contain insufficient information necessary to establish the probable cause. There has been no evidence of drug-induced hepatotoxicity in the pioglitazone hydrochloride controlled clinical trial database to date [see Adverse Reactions (6.1)]. 

Patients with type 2 diabetes may have fatty liver disease or cardiac disease with episodic congestive heart failure, both of which may cause liver test abnormalities, and they may also have other forms of liver disease, many of which can be treated or managed. Therefore, obtaining a liver test panel (serum alanine aminotransferase [ALT], aspartate aminotransferase [AST], alkaline phosphatase, and total bilirubin) and assessing the patient is recommended before initiating pioglitazone therapy. In patients with abnormal liver tests, pioglitazone hydrochloride should be initiated with caution. 

Measure liver tests promptly in patients who report symptoms that may indicate liver injury, including fatigue, anorexia, right upper abdominal discomfort, dark urine or jaundice. In this clinical context, if the patient is found to have abnormal liver tests (ALT greater than 3 times the upper limit of the reference range), pioglitazone hydrochloride treatment should be interrupted and investigation done to establish the probable cause. Pioglitazone tablets should not be restarted in these patients without another explanation for the liver test abnormalities.

Patients who have serum ALT greater than three times the reference range with serum total bilirubin greater than two times the reference range without alternative etiologies are at risk for severe drug-induced liver injury, and should not be restarted on pioglitazone. For patients with lesser elevations of serum ALT or bilirubin and with an alternate probable cause, treatment with pioglitazone can be used with caution.
The present invention relates to antigen-binding molecules, preferably antibodies or antigen-binding fragments thereof, that selectively bind to 8-oxo-adenine. The antibodies disclosed here recognize 8-oxo-adenine within a variety of nucleic acid substrates, including single-strand and double-strand RNA and DNA and 8-oxo-adenine-nucleotides. The invention further relates to immunocohjugates comprising the antigen-binding molecules. The antigen-binding molecules and immunoconjugates of the invention may be employed alone, or in combination for use in 8-oxo-adenine detection and quantification assays. The present invention also relates to nucleotide sequences encoding anti-8-oxo-adenine antibodies, and host cells, cell-free transcription-translation systems and cell-free translation systems containing the nucleotide sequences, and methods of making anti-8-oxo-adenine-antibodies. The antigen-binding molecules, antibodies and compositions of the invention are useful in DNA or RNA quality control assays and diagnostic or monitoring applications for diseases in which levels of 8-oxo-adenine are altered. The present invention also obviates the requirement for binding substrate denaturation.
This is an eight-week intervention involving two sessions per week, hosted virtually on Zoom. The main session is scheduled to last 60 min and the session hosts remain online for an additional 15 minutes to answer individual questions on the management of symptoms and activities that have not been addressed during the main session. The content was developed based on clinical experience, best available evidence for the management of specific symptoms (chronic fatigue, post-exertional malaise, breathing discomfort) in other conditions, including post-viral syndromes, and the current understanding and recommendations for rehabilitation of people living with long COVID. Long COVID can be isolating, and challenges often interfere with everyday lifestyle and socialization. The investigators have incorporated breakout rooms (where the group is divided into two smaller groups based on current activity limitations) to include elements of peer support.
A ballistocardiogram (BCG), a measurement of cardiogenic whole body movements, is a technique that enables non-invasive cardiovascular monitoring. A main challenge of the BCG signal is that its morphology and amplitude are sensitive to the posture and/or position of the subject during the recording period. The effects of posture on the BCG measured from a subject standing on a weighing scale have been investigated in the literature, but the effects of body posture and/or position on BCG signals measured from a subject lying in a bed have not been quantified. A contemplated method for bed-based BCG recordings includes (1) creating templates for standing BCG signals obtained from subjects in a prior study, and (2) quantifying the distance between these templates and BCG waveforms obtained in different body positions on the bed for a new set of subjects. In addition, an array processing technique is presented, which includes the application of Gaussian weights on a joint probability density function (PDF) and the similarity score called the q-value to assess those PDFs. The Gaussian curve weights the joint probability according to the reference value obtained from the previous inter-beat-interval (IBI) estimations. The PDFs are selected and combined according to their reliability measured by q-values. This array processing significantly reduces the FIR estimation error by comparing the performance of selective channel combinations to the existing multi-channel algorithm.
Will receive IIV this year. Includes only 9-17 year olds (unless shortages of LAIV encountered). Prior history includes vaccine failures, vaccinated/uninfected and unvaccinated/uninfected last year. PBMC available for those who were infected last year, only 9-17 year olds.
The present invention contemplates methods and compositions for removing a tattoo. In one aspect, the present invention contemplates the use of a macrophage cell disrupter, optionally with an IRM for removing a tattoo. Both the IRM and the macrophage cell disrupter may be admixed with an adhesive. In one aspect the present invention contemplates a composition comprising an adhesive and an IRM. Such composition can be found in a kit for removal of a tattoo. In any of the embodiments herein, low dose IRMs are preferred.
<P>PROBLEM TO BE SOLVED: To provide a new prophylactic or therapeutic agent having effects on diseases based on cerebrovascular disorder and a health food for prevention or treatment.  <P>SOLUTION: (1) The prophylactic or therapeutic agent for diseases based on cerebrovascular disorder comprises a liquid culture solution (derived component) of mycelium of Phellinus Linteus as an active ingredient. (2) The cerebrovascular disorder is cerebral infarction, cerebral hemorrhage, subarachnoid hemorrhage or cerebral edema in the prophylactic or therapeutic agent described in (1). (3) The health food for preventing or treating diseases based on cerebrovascular disorder comprises a liquid culture solution (derived component) of a mycelium of Phellinus Linteus as an active ingredient. (4) The disease based on cerebrovascular disorder is cerebral infarction, cerebral hemorrhage, subarachnoid hemorrhage or cerebral edema, in the health food for preventing or treating diseases based on cerebrovascular disorder described in (3).  <P>COPYRIGHT: (C)2009,JPO&INPIT